IND-Enabling Studies

IND-Enabling Studies describe the set of preclinical experiments and development activities conducted to support submission of an Investigational New Drug application, allowing a candidate therapy to enter first-in-human clinical trials. These studies typically include pharmacology demonstrating biological activity, toxicology assessing safety margins, pharmacokinetic and pharmacodynamic profiling, and chemistry, manufacturing, and controls work establishing product quality.

The pharmaceutical industry designs IND-enabling packages to meet regulatory expectations while balancing speed, cost, and scientific confidence. Toxicology studies often include single-dose and repeat-dose assessments, safety pharmacology evaluating cardiovascular or respiratory effects, and evaluation of genotoxicity where relevant. Biologics may require specialised assessments for immunogenicity, cytokine release risk, or biodistribution. Manufacturing readiness includes process development, analytical method qualification, stability studies, and preparation of clinical-grade material under GMP. Successful IND-enabling studies represent a key milestone confirming programme maturity and readiness for clinical evaluation.